34 Chapter 2 24. Meziani F, Delabranche X, Asfar P, Toti F. Bench-to-bedside review: circulating microparticles--a new player in sepsis? Critical care (London, England). 2010;14(5):236. 25. Opal SM, van der Poll T. Endothelial barrier dysfunction in septic shock. Journal of internal medicine. 2015;277(3):277-93. 26. Levi M, Poll T. Coagulation in patients with severe sepsis. Seminars in thrombosis and hemostasis. 2015;41(1):9-15. 27. Biemond BJ, Levi M, Ten Cate H, Van der Poll T, Buller HR, Hack CE, et al. Plasminogen activator and plasminogen activator inhibitor I release during experimental endotoxaemia in chimpanzees: effect of interventions in the cytokine and coagulation cascades. Clinical science (London, England : 1979). 1995;88(5):587-94. 28. Coughlin SR. Thrombin signalling and protease-activated receptors. Nature. 2000;407(6801):258-64. 29. Kaneider NC, Forster E, Mosheimer B, Sturn DH, Wiedermann CJ. Syndecan-4-dependent signaling in the inhibition of endotoxin-induced endothelial adherence of neutrophils by antithrombin. Thrombosis and haemostasis. 2003;90(6):1150-7. 30. Esmon CT. New mechanisms for vascular control of inflammation mediated by natural anticoagulant proteins. The Journal of experimental medicine. 2002;196(5):561-4. 31. Yuksel M, Okajima K, Uchiba M, Horiuchi S, Okabe H. Activated protein C inhibits lipopolysaccharide-induced tumor necrosis factor-alpha production by inhibiting activation of both nuclear factor-kappa B and activator protein-1 in human monocytes. Thrombosis and haemostasis. 2002;88(2):267-73. 32. Murakami K, Okajima K, Uchiba M, Johno M, Nakagaki T, Okabe H, et al. Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 1996;87(2):642-7. 33. Sanchez T. Sphingosine-1-Phosphate Signaling in Endothelial Disorders. Curr Atheroscler Rep. 2016;18(6):31. 34. Mikacenic C, Hahn WO, Price BL, Harju-Baker S, Katz R, Kain KC, et al. Biomarkers of Endothelial Activation Are Associated with Poor Outcome in Critical Illness. PloS one. 2015;10(10):e0141251. 35. Sorensen OE, Borregaard N. Neutrophil extracellular traps - the dark side of neutrophils. The Journal of clinical investigation. 2016;126(5):1612-20. 36. Hotchkiss RS, Monneret G, Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nature reviews Immunology. 2013;13(12):862-74. 37. Davenport EE, Burnham KL, Radhakrishnan J, Humburg P, Hutton P, Mills TC, et al. Genomic landscape of the individual host response and outcomes in sepsis: a prospective cohort study. The Lancet Respiratory medicine. 2016;4(4):259-71. 38. Scicluna BP, van Vught LA, Zwinderman AH, Wiewel MA, Davenport EE, Burnham KL, et al. Classification of patients with sepsis according to blood genomic endotype: a prospective cohort study. The Lancet Respiratory medicine. 2017; Epub ahead of print. 39. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in patients who die of sepsis and multiple organ failure. Jama. 2011;306(23):2594-605. 40. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proceedings of the National Academy of Sciences of the United States of America. 2009;106(15):6303-8. 41. Carson WF, Cavassani KA, Dou Y, Kunkel SL. Epigenetic regulation of immune cell functions during post-septic immunosuppression. Epigenetics. 2011;6(3):273-83. 42. Foster SL, Hargreaves DC, Medzhitov R. Gene-specific control of inflammation by TLRinduced chromatin modifications. Nature. 2007;447(7147):972-8.
RkJQdWJsaXNoZXIy MTk4NDMw